
    
      The trial is designed to demonstrate that the CardioMEMS Sensor can be positioned in the
      right or left pulmonary artery, and that Sensor pressure measurements correlate to
      standardized methods of intra-cardiac pressure measurements post-sensor implant and at the 60
      day visit. Safety will be monitored by the occurrence of adverse events throughout the trial.
    
  